venBio Partners LLC Long-Term Concentrated

CIK: 0001776382 · Show all filings

Period: Q2 2023 (← Previous) (Next →)

Filing Date: Aug 14, 2023

Total Value ($000): $276,308 (100.0% shares, 0.0% debt)

Holdings (7)

— ACELYRIN INC 29.2%

Value ($000) $80,616 Shares 3,857,230 Est. Cost $20.90 Unrealized —

ALXO ALX ONCOLOGY HLDGS INC 26.4%

Value ($000) $72,846 Shares 9,699,925 Est. Cost $39.31 Unrealized -83.3%

PHVS PHARVARIS N V 23.4%

Value ($000) $64,567 Shares 4,264,672 Est. Cost $21.29 Unrealized -54.8%

HRMY HARMONY BIOSCIENCES HLDGS IN 13.2%

Value ($000) $36,436 Shares 1,035,396 Est. Cost $36.46 Unrealized -5.3%

VTYX VENTYX BIOSCIENCES INC 5.0%

Value ($000) $13,908 Shares 424,032 Est. Cost $18.95 Unrealized +81.9%

— ELEVATION ONCOLOGY INC 1.6%

Value ($000) $4,430 Shares 2,914,255 Est. Cost $9.24 Unrealized —

— IMPEL PHARMACEUTICALS INC 1.3%

Value ($000) $3,505 Shares 2,759,791 Est. Cost $8.85 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	ACELYRIN INC	3,857,230	$80,616	29.2%	$20.90	—	COM	00445A100
ALXO	ALX ONCOLOGY HLDGS INC	9,699,925	$72,846	26.4%	$39.31	-83.3%	COM	00166B105
PHVS	PHARVARIS N V	4,264,672	$64,567	23.4%	$21.29	-54.8%	COM	N69605108
HRMY	HARMONY BIOSCIENCES HLDGS IN	1,035,396	$36,436	13.2%	$36.46	-5.3%	COM	413197104
VTYX	VENTYX BIOSCIENCES INC	424,032	$13,908	5.0%	$18.95	+81.9%	COM	92332V107
—	ELEVATION ONCOLOGY INC	2,914,255	$4,430	1.6%	$9.24	—	COM	28623U101
—	IMPEL PHARMACEUTICALS INC	2,759,791	$3,505	1.3%	$8.85	—	COM	45258K109